Economic and health outcomes of capsule endoscopy:  Opportunities for improved management of the diagnostic process for obscure gastrointestinal bleeding by Goldfarb, Neil I. et al.
Thomas Jefferson University
Jefferson Digital Commons
College of Population Health Faculty Papers Jefferson College of Population Health
September 2002
Economic and health outcomes of capsule
endoscopy: Opportunities for improved
management of the diagnostic process for obscure
gastrointestinal bleeding
Neil I. Goldfarb
Thomas Jefferson University
Amy Phillips
Abbott Laboratories
Mitchell Conn
Thomas Jefferson University
Blair S. Lewis
David B. Nash
Thomas Jefferson University, David.Nash@jefferson.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/healthpolicyfaculty
Part of the Health Services Research Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
College of Population Health Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Goldfarb, Neil I.; Phillips, Amy; Conn, Mitchell; Lewis, Blair S.; and Nash, David B., "Economic and
health outcomes of capsule endoscopy: Opportunities for improved management of the diagnostic
process for obscure gastrointestinal bleeding" (2002). College of Population Health Faculty Papers.
Paper 10.
http://jdc.jefferson.edu/healthpolicyfaculty/10
DISEASE MANAGEMENT
Volume 5, Number 3, 2002
© Mary Ann Liebert, Inc.
Economic and Health Outcomes of Capsule Endoscopy:
Opportunities for Improved Management of the
Diagnostic Process for Obscure Gastrointestinal Bleeding
NEIL I. GOLDFARB, B.A.,1 AMY PHILLIPS, Pharm.D.,2 MITCHELL CONN, M.D.,3
BLAIR S. LEWIS, M.D.,4 and DAVID B. NASH, M.D., M.B.A.1,5
ABSTRACT
The estimated annual incidence of gastrointestinal bleeding in the United States is approxi-
mately 100 episodes per 100,000 persons, resulting in 300,000 hospitalizations annually. Di-
agnostic tools such as radiologic studies and endoscopic examination often fail to identify a
source of bleeding, resulting in a cycle of repetitive testing over months or even years. Costs
associated with the diagnostic process, and with interim treatment for anemia and other symp-
toms, can be significant. The diagnostic process also takes a toll on the patient, in terms of
worry, pain, and discomfort. Capsule endoscopy, a technology that received FDA clearance
in August, 2001, consists of a video capsule that is ingested by the patient, and that transmits
images to a wireless data recorder worn on the belt. The recorded stream of approximately
50,000 images can be reviewed on a computer workstation by a physician to identify nature
and location of potential sources of bleeding. This paper presents a framework for economic
analysis of this new technology. First, we present a review of the literature on the current di-
agnostic methods. Next, we present a conceptual model for examining contributors to costs
in diagnosing obscure intestinal bleeds. We conclude by exploring the potential economic
impact of the technology. Analysis of data from the first U.S. clinical trial of capsule en-
doscopy demonstrates its high diagnostic yield, and patient satisfaction. While further study
is required, this analysis indicates that capsule endoscopy may reduce total medical utiliza-
tion and costs and improve patient quality of life, when used for appropriate indications.
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THE DIAGNOSIS OF OBSCURE
GASTROINTESTINAL BLEEDING
THE ANNUAL INCIDENCE of gastrointestinal(GI) bleeding in the United States has been
conservatively estimated at approximately 100
episodes per 100,000 persons, accounting for
approximately 300,000 hospitalizations per
year.1 The actual incidence may be higher.
Mass screening programs for colorectal cancer
have revealed rates of fecal occult bleeding for
asymptomatic individuals ranging between 2%
and 8% of the at-risk population.2
Obscure bleeding refers to intermittent or
1Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, Pennsylvania. 2Center
for Pharmaceutical Appraisal and Outcomes Research, Abbott Laboratories, Abbott Park, Illinois. 3Division of Gas-
troenterology, Thomas Jefferson University, Philadelphia, Pennsylvania. 4New York, New York. 5Dr. Raymond C.
and Doris N. Grandon, Professor of Health Policy, Thomas Jefferson University, Philadelphia, Pennsylvania.
chronic bleeding of unknown origin with neg-
ative endoscopy, colonoscopy, and/or small
bowel series results.3,4 Obscure bleeding can be
subcategorized into either (1) obscure-occult
[recurrent iron-deficiency anemia (IDA) and/
or recurrent positive fecal occult blood test
(FOBT) results] or (2) obscure-overt (recurrent
passage of visible fecal blood).3
About 70–80% of small bowel bleeding cases
are due to vascular lesions. Arteriovenous mal-
formations account for about 66% of small
bowel vascular lesions. Vascular lesions tend to
be more common in elderly patients, patients
with chronic renal failure, and patients diag-
nosed with inherited disorders.5,6 Even though
only about 5–7% of all GI tumors are located in
the small bowel, small bowel tumors are the
second most common cause of obscure bleed-
ing.5 The most common benign tumors of the
small bowel include adenomas, leiomyomas,
and lipomas. Of all malignant GI tumors, less
than 2% are located in the small bowel. The
most common type, adenocarcinomas, account
for 40% of all small bowel carcinomas.5
A variety of diagnostic tools and procedures
exist for identifying the source of obscure
bleeding, including radiologic studies, en-
teroscopy, and nuclear scans.
Radiologic studies
The small bowel series, which involves x-
rays after the patient has swallowed a contrast
medium, has been shown to have a low diag-
nostic yield, about 5%, for the detection of small
intestinal bleeding and a high false-negative
rate of 41.6%.7 Enteroclysis differs from small
bowel series in that the contrast material is ad-
ministered via a small tube placed directly in
the proximal intestine.8 Enteroclysis is not very
helpful in detecting vascular lesions, but can be
useful in identifying mucosal damage or small
bowel tumors, since it allows for visualization
of the entire small bowel, including the portion
that cannot be reached by an endoscope.5
While it is often used in combination with en-
teroscopy to improve diagnostic yield, the im-
provement may be minimal. For example, one
study found a diagnostic yield of enteroscopy
of 54%, versus a yield of 57% when enteroscopy
was combined with enteroclysis.9 Some disad-
vantages of enteroclysis compared with small
bowel series include greater radiation expo-
sure, greater patient discomfort (gagging and
wretching), and longer procedure time.10
Push enteroscopy
Push enteroscopy, the most commonly used
endoscopic diagnostic procedure for examining
the small bowel, is appropriately named because
the operator must “push” the diagnostic instru-
ment through the upper GI tract into the small
bowel via the oral route.11 Several studies have
indicated that the overall diagnostic yield of
push enteroscopy in identifying obscure bleed-
ing lesions is between 38% and 75%4 (Table 1).
However, these diagnostic yields may reflect all
types of lesions that were identified, even in-
cluding those located prior to the small bowel
and not related to the source of the obscure
bleed. Thus, the true diagnostic yield of push en-
teroscopy for work-up of obscure bleeding in the
small bowel may be more in the range of 15–35%.
Advantages to using push enteroscopy include
its relative ease of use, time of performing the
procedure (most examinations take less than 60
minutes), and the ability to obtain biopsy sam-
ples and conduct therapeutic interventions (i.e.,
electrocoagulation, polypectomy).7,11 In addi-
tion, the procedure is relatively safe and has a
low incidence of complications.8
Many of the reported complications with
push enteroscopy involve the use of overtubes,
which keep the enteroscope from curling in the
stomach, thus allowing for deeper penetration
into the small bowel. Unfortunately, the use of
overtubes may cause mucosal damage to the
GI tract.11 Other disadvantages associated with
enteroscopy include the need for patient seda-
tion, and that significant patient discomfort
may occur. However, the most significant dis-
advantage is that the enteroscope has limited
reach and may only examine as little as one-
third of the small bowel’s total length, which is
approximately 22 feet.
Sonde enteroscopy
Sonde enteroscopy involves transnasal in-
sertion of a longer endoscope, which is ad-
vanced through the digestive tract to the distal
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portion of the small bowel by peristalsis, over
an approximately 8-hour period. The physician
slowly withdraws the endoscope while view-
ing the small bowel.7 The diagnostic yield of
sonde enteroscopy (Table 1) is reported to be
between 26% and 54%.8 Sonde enteroscopy is
not often used today in clinical practice owing
to discomfort to the patient and clinical limita-
tions to the procedure.5 For example, because
the examination of the small bowel occurs dur-
ing the withdrawal of the enteroscope, the
sonde enteroscope cannot be readvanced dur-
ing the procedure.7 This limits the view to only
50–70% of the mucosal surface.11 Further, very
few types of sonde enteroscopes are available,
the instrument is costly to repair, and the pro-
cedure time is significant.7,9 Complications are
uncommon, but perforations of the bowel have
been reported.8
Intraoperative enteroscopy
Intraoperative enteroscopy is considered the
“gold standard” for small bowel examination
because most, if not all, of the small bowel can
be visualized.5 Because it is an invasive proce-
dure, intraoperative enteroscopy is most often
used in patients with obscure bleeding who, af-
ter multiple testing, remain undiagnosed and
continue to require blood transfusions.11 Since
laparotomy is involved, the procedure requires
the assistance of both an endoscopist and sur-
geon.11 While the actual exam time may be as
low as 30 minutes for the endoscopist,5 prepa-
ration, intra- and postoperative surgical time
and costs can be significant. Because intraop-
erative enteroscopy allows for the inspection of
the entire mucosal surface, it has been reported
that intraoperative enteroscopy has a diagnos-
tic yield of 70–100% in patients with obscure
bleeding8 (Table 1). The array of complications
that can occur with intraoperative enteroscopy
show that this procedure should only be per-
formed by experienced endoscopists and sur-
geons in carefully selected patients. In addition,
postoperative deaths with intraoperative en-
teroscopy have been reported as high as 11%,
but many studies fail to report mortality with
intraoperative enteroscopy.8
Nuclear scans and angiography
Radioisotope bleeding scans may be useful
in detecting bleeding sources of obscure ori-
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TABLE 1. YIELD FOR COMMON DIAGNOSTIC PROCEDURES FOR OBSCURE GI BLEEDING
Procedure, study Total Source identified Yield (%)
Push enteroscopy5,8,11,12
Foutch et al.13 (1990) 39 15 15/39 (38)
Barkin et al.14 (1992) 28 21 21/28 (75)
Harris et al.15 (1994) 31 19 19/31 (61)
Schmit et al.16 (1996) 83 49 49/83 (59)
Vakil et al.17 (1997) 29 18 18/29 (62)
Chak et al.6 (1998) 129 91 91/129 (71)
Shackel et al.18 (1998) 44 23 23/44 (52)
Zaman and Katon12 (1998) 95 39 39/95 (41)
Sonde enteroscopy7,8,11
Barthel et al.19 (1990) 18 5 5/18 (28)
Gostout et al.20 (1991) 35 9 9/35 (26)
Morris et al.21 (1992) 65 25 25/65 (38)
Gostout et al.22 (1993) 24 13 13/24 (54)
Intraoperative enteroscopy8
Bowden et al.23 (1980) 18 16 16/18 (89)
Lau et al.24 (1987) 15 12 12/15 (80)
Flickinger et al.25 (1989) 14 13 13/14 (93)
Desa et al.26 (1991) 12 10 10/12 (83)
Lewis et al.27 (1991) 23 20 20/23 (87)
Ress et al.28 (1992) 44 31 31/44 (70)
Szold et al.29 (1992) 30 28 28/30 (93)
Lopez et al.30 (1996) 16 14 14/16 (88)
gin. The most commonly used method is the
99mTc-labeled erythrocyte scan.8 The sensitiv-
ity of this nuclear medicine scan can range
from 50% to 90% in detecting the presence and
approximate site of bleeding, pending that the
test is performed during active bleeding.5 The
source must have an active bleeding rate of
0.1–0.4 mL/min to generate a positive scan re-
sult.8 Conversely, the scan may produce a
normal result if the bleeding is intermittent.
The sensitivity of this test in identifying on-
going GI bleeding ranges between 30% and
86%.5 Angiography can also be used to per-
form therapeutic interventions by using em-
bolization or vasopressin infusion to treat the
bleeding site.5 The administration of antico-
agulants, vasodilators, or clot-lysing agents
may enhance the diagnostic yield of this pro-
cedure; however, the increased risk of bleed-
ing complications with this technique limits
its use.8
The American Gastroenterological Associ-
ation (AGA) has published an algorithm for
diagnosing both obscure-occult and obscure-
overt bleeding3 (Fig. 1). Initial diagnostic
evaluation often involves repeated colono-
scopy and upper endoscopy procedures 
before advancing to the small bowel. These
repeat procedures often identify the bleeding
source that was missed in the initial in-
vestigation.8 It is estimated that as many as
30% of upper lesions during upper en-
doscopy and 3% of colonic lesions during
colonoscopy are overlooked during the initial
procedure.4 Yet another study that repeated
upper endoscopy and colonoscopy proce-
dures after an initial normal examination
failed to locate a bleeding lesion.13 The deci-
sion to perform a repeat endoscopy often de-
pends on the skill and experience of the ini-
tial endoscopist. Some investigators may
elect to perform enteroscopy instead of re-
peating the endoscopy.8 Despite multiple di-
agnostic evaluations with upper endoscopy,
colonoscopy, and barium studies, approxi-
mately 5% of patients will continue to expe-
rience unidentified obscure bleeding.31
Because of the limitations of traditional di-
agnostic tests discussed above, it may take con-
siderable time to diagnose a patient who pre-
sents with obscure GI bleeding. The median
time to diagnose patients with obscure-overt
bleeding has been estimated as two years, with
a range from one month to eight years.8 As a
consequence of this extended time to diagno-
sis, patients may be forced to undergo numer-
ous diagnostic tests and evaluations before a
bleeding source can be identified. For example,
in one study,13 39 patients undergoing push-
enteroscopy for unidentified obscure bleeding
had a total of 277 diagnostic tests performed,
for an average of 7.3 tests per patient. At the
conclusion of the study, 49% of the patients
continued to have an unknown bleeding
source. The cycle of repeat testing also can be
associated with interim treatments, especially
hospitalizations and outpatient treatments for
anemia.8 In a study of 14 patients with obscure
bleeding, hospital admissions ranged from two
to 10 (mean 5 5), and units of blood transfused
ranged from 6 to 200 (mean 5 46) during the
6-year period prior to undergoing intraopera-
tive enteroscopy.25
COSTS ASSOCIATED WITH
DIAGNOSING OBSCURE
GASTROINTESTINAL BLEEDING
The current medical literature lacks detailed
information on the costs associated with diag-
nosing obscure GI bleeding. The most compre-
hensive review of the economic literature for
the period 1985–1995 identified limited infor-
mation of value in understanding the costs, and
was not limited to obscure bleeding.32 In Fig-
ure 2, we present a conceptual model showing
how current diagnostic tools and protocols im-
pact on costs. The model is based on literature
review and consultation with clinicians, and is
intended to provide a framework for conduct-
ing economic evaluation of both current and
new diagnostic technologies for obscure bleed.
The model, which takes a societal perspective,
includes a flowchart demonstrating key con-
tributors to the direct medical costs of screen-
ing, and also identifies key indirect medical
and non-medical cost categories. Although pat-
terns of care flow may vary across provider set-
tings (e.g., some primary care physicians may
order diagnostic tests and continue to monitor
care themselves, rather than referring the pa-
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tient to gastroenterology for work-up), the cat-
egories of contributors to cost are expected to
be similar across settings, systems, and geo-
graphic regions.
Direct medical costs
A bleeding event, as noted previously, may
be defined as a positive finding on an occult
screening exam, or the visible presence of blood
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FIG. 1. American Gastroenterological Association algorithm for evaluation of obscure bleeding, published January,
2000. *The decision to repeat upper endoscopy and/or colonoscopy may depend on the skill and expertise of the ini-
tial endoscopist; push enteroscopy can replace upper endoscopy at this juncture; and small bowel biopsy is indicated
in patients with clinical or endoscopic evidence of celiac sprue or unexplained IDA. **Repeat routine endoscopy may
be performed in actively bleeding patients at the discretion of the endoscopist. ***Push enteroscopy and/or Sonde
enteroscopy may be performed, depending on operator and institution expertise; enteroclysis can complement en-
teroscopy and improve the diagnostic yield.
in the stool. An initial bleeding event, or repeat
episodes, may trigger visits to a healthcare
provider. Typically, the initial presentation (or
identification of occult blood) will take place in
a primary care provider setting or an emer-
gency department. Initial evaluation may be
conducted by the intake provider (e.g., a fam-
ily physician performing a flexible sigmoido-
scopic exam), but the typical case of obscure
bleed ultimately will be referred to gastroen-
terology for work-up. In some cases, “intake”
also may result in inpatient admission for acute
treatment of severe anemia.
As noted in the previous section, a range of
diagnostic tests are available for clinical work-
up, including endoscopy and other gastroen-
terologic scoping methods, radiologic studies,
and exploratory surgery. A series of tests and
examinations, including repeat administra-
tions of the same diagnostic exam, are typically
needed in order to rule out potential sources of
bleeding, and to establish the site(s) of bleed-
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FIG. 2. Costs associated with diagnosing obscure bleeds.
ing. In some cases, exploratory surgery, in-
cluding intraoperative enteroscopy, may be
warranted. When these diagnostic procedures
are performed on an inpatient or same-day sur-
gery basis, cost may be increased by require-
ments for preadmission testing. In addition, be-
cause of their invasive nature, these diagnostic
examinations can result in complications re-
quiring treatment, ranging from pain and dis-
comfort to perforation or infection.
Concurrent with diagnostic work-up, which
may take place over weeks, months, or even
years until a source of bleeding can be estab-
lished, treatment may be required. Pharmaceu-
tical interventions, including over-the-counter
medications, may include iron supplementation
for mitigating the impact of bleeding, stool soft-
eners and laxatives, and, in some cases, seda-
tion to control anxiety.
Indirect medical costs
The medical costs identified above are asso-
ciated with the process of ruling out potential
sources of bleeding and determining both the
site and etiology of bleeding. Additional med-
ical costs may result from delayed treatment,
(e.g., the delay in identifying a small bowel ma-
lignancy). The published literature has yet to
address this issue from an economic perspec-
tive.
Non-medical costs
In addition to the costs associated with med-
ical care, consideration must be given to the hu-
manistic and societal costs of the diagnosis pro-
cess for obscure bleed. Main categories of these
costs include:
 Lost workplace and non-workplace produc-
tivity, associated with time spent scheduling
medical appointments, preparing for exam-
ination, undergoing testing and treatment,
and recuperation.
 Worry and decreased quality of life, associ-
ated with concern over the lack of a diagno-
sis, potential for the cause of bleeding to be
life-threatening, and being subjected to re-
peat testing.
 Pain and discomfort associated with prepa-
ration for testing (fasting, clearing the GI
tract), the testing procedure, and recupera-
tion.
 Travel, parking, child-care, and other out-of-
pocket costs for the patient.
ECONOMIC ANALYSIS OF
CAPSULE ENDOSCOPY
Description of the technology and acquisition costs
Capsule endoscopy is a new diagnostic tech-
nology, FDA-cleared for the diagnosis of ob-
scure bleeding in 2001. The manufacturer of
capsule endoscopy technology is Given Imag-
ing Ltd., a GI diagnostics company headquar-
tered in Yoqneam, Israel. The Given Diagnos-
tic Imaging System includes the M2A® Capsule
Endoscope, the DataRecorder, Sensor Array,
and RAPID™ (Reporting and Processing of Im-
ages and Data) WorkStation. The Capsule 
Endoscope is a disposable video endoscope
measuring 113 26 mm. Like traditional endo-
scopes, the Capsule Endoscope contains an in-
tegrated light source, video chip, energy
source, and transmitter. Like the sonde endo-
scope, it is ingested by the patient and advances
through the GI tract through peristalsis. It pro-
vides direct color video images of the GI mu-
cosa at a rate of 2 images per second for ap-
proximately 8 hours. The capsule is naturally
excreted. The Sensor Array is worn on the ab-
domen and receives images and data from the
capsule endoscope. The sensors pass the video
images to the DataRecorder, which the patient
wears on a belt. The ambulatory belt permits
patients to continue with normal daily activities
during the examination. After approximately 8
hours, the patient procedure is complete, and
the DataRecorder can download approximately
50,000 images with localization and diagnostic
data to the RAPID WorkStation. The RAPID
WorkStation is equipped with Given’s propri-
etary RAPID Application Software, which 
processes the data downloaded from the
DataRecorder. The output allows physicians to
view the endoscopy video, save individual im-
ages and short video clips, save findings, and
print reports. The physician endoscopy review
time is approximately 1.5 hours.
A complete installation of the capsule en-
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doscopy technology at a clinical site requires
an initial supply of disposable capsules, one or
more DataRecorders with Sensor Array, and a
WorkStation for reading images and data from
the recorder. Given’s current pricing for the
technology includes $19,950 in fixed costs for
the WorkStation and DataRecorder kit with
Sensor Array, and variable costs of $450 for
each disposable Capsule Endoscope. The fixed
cost of acquiring the technology is similar to
the acquisition cost of other diagnostic tech-
nologies for obscure bleed. For example, the av-
erage cost for a traditional enteroscope is ap-
proximately $29,000.
From a provider’s perspective, the cost of the
technology per test will depend in part on the
volume of procedures performed, as illus-
trated in Table 2. The cost in Table 2 is based
on the pricing above, and the assumption that
a site would purchase one recorder for every
100 procedures performed in a year. The
workstation and recorder costs are amortized
over 3 years, although for the purposes of
simplicity of presentation, a discount rate is
not applied.
As can be seen, the cost driver for economic
analysis of the Given technology to a large ex-
tent is the variable cost of the disposable Cap-
sule Endoscope ($450). Additional costs for the
technology include labor time and facility over-
head allocation for:
 Physician or nurse to prepare the patient
with thorough explanation of procedure 
instructions
 Physician or nurse to prepare the patient by
shaving the abdomen to place the Sensor Ar-
ray
 Nurse or technician to disinfect the Sensor
Array, DataRecorder, and recorder belt
 Nurse or technician to set up and attach Sen-
sor Array, DataRecorder, and recorder belt
for patient
 Physician to discuss ingestion technique and
introduce Capsule Endoscope to patient
 Physician or nurse to receive patient for dis-
assembly of components and receive feed-
back
 Physician or nurse to prepare WorkStation
and download DataRecorder for image pro-
cessing
 Physician or nurse to recharge DataRecorder
batteries and reprocess equipment
 Physician to review capsule endoscopy video
and diagnostic data for 1.5 hours
The intensity of review by a professional of
capsule endoscopy of the small intestine is sig-
nificant, owing to the number of images (more
than 50,000) that are relayed by the Capsule En-
doscope. The labor involved in the test mirrors
a gastroenterologist’s activity in performing
sonde enteroscopy. While total physician time
required for the capsule endoscopy of the small
intestine review exceeds that of sonde en-
teroscopy, this time can be spread over hours
or days, and images can be viewed repeatedly,
unlike other forms of enteroscopy.
From a payor perspective, CPT code 44376 is
used for sonde enteroscopy and is described as
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TABLE 2. RELATIONSHIP BETWEEN VOLUME OF TESTS PERFORMED AND EQUIPMENT COST (IN DOLLARS)
per test
Number of
tests per Capsule Workstation Recorder Equipment
year cost cost cost Total cost cost per test
25 11,250 4,833 1,817 17,900 716
50 22,500 4,833 1,817 29,150 583
75 33,750 4,833 1,817 40,400 539
100 45,000 4,833 1,817 51,650 517
150 67,500 4,833 3,633 75,967 506
200 90,000 4,833 3,633 98,467 492
250 112,500 4,833 3,633 120,967 484
“Small intestinal endoscopy, enteroscopy be-
yond second portion of duodenum, including
ileum; diagnostic.” As shown in the 2001 edi-
tion of Medical Fees in the United States, pub-
lished by Practice Management Information
Corporation (PMIC), the national average for
the usual and customary professional fee for
CPT 44376 is $847. The fees vary regionally. For
example, in Long Island, New York, the usual
and customary fee is $1,185 for the same pro-
cedure. In 2001, the average Medicare profes-
sional fee reimbursement for CPT 44376 was
$320 nationally, and $383 in New York. A sep-
arate CPT code for capsule endoscopy of the
small intestine and an HCPCS code for the Cap-
sule itself have yet to be established.
How might the cost of capsule endoscopy
compare with the cost of diagnosing obscure
bleeding patients with traditional exams? Since
the procedural cost of sonde enteroscopy and
capsule endoscopy are similar, in order to an-
swer this question effectively, one must con-
sider the diagnostic yield and cost-effectiveness
of capsule endoscopy compared with tradi-
tional diagnostic tools.
The potential for cost savings
The placement of capsule endoscopy within
a clinical guideline needs to be sensitive to both
the effectiveness of the test and its cost-effec-
tiveness. The conceptual care flow model pre-
sented in the previous section is useful in iden-
tifying potential areas for cost savings that
could result from the introduction of capsule
endoscopy into the clinical diagnosis tool kit
for obscure bleeds:
 Improved diagnostic yield and reduction in
the occurrence of repeat, inconclusive test-
ing, associated not only with the clarity of
the images obtained by the Capsule, but also
with the Capsule’s ability to traverse the en-
tire small bowel (whereas endoscopic exams
leave part of the small bowel unexamined)
 Improved diagnostic precision in being able
to confirm the source of bleeding, and/or
rule-out certain etiologies
 Earlier diagnosis of potentially adverse con-
ditions, such as malignancies of the small
bowel
 Reduced complications associated with the
diagnostic procedure, such as intestinal tears
resulting from placement of the enteroscope,
and/or infection
 Reduced losses in productivity associated
with undergoing testing and repetitive ex-
aminations, and reduced losses in quality of
life associated with both testing and worry
 Reduced pain and discomfort associated
with the diagnostic procedures
Clinical trial data analysis
The first U.S. trial of capsule endoscopy
provides data confirming the potential cost
savings and quality of life improvement as-
sociated with the new technology. In this trial,
patients with obscure GI bleeding of un-
known origin despite repeated testing were
examined using capsule endoscopy, which
was followed within one week by push en-
teroscopy, so that the diagnostic yield of the
two procedures could be compared. Push en-
teroscopy was selected for comparison as the
most equivalent diagnostic procedure in the
current clinical toolkit. Although intraopera-
tive enteroscopy, as discussed above, is the
diagnostic gold standard, it is less often per-
formed, particularly in early stages of diag-
nosing obscure bleeding, owing to its higher
cost, risk, and patient impact.
Of the 21 patients enrolled in the trial, one
female was excluded owing to a technology
malfunction. Of the remaining 20 patients, 11
were females and nine were males. The mean
age was 61 years. The patients in the trial had
significant history of bleeding: The mean
length of time since first recognition of bleed-
ing was 2.7 years, after excluding one outlier
who had gone 12 years since first bleed. Table
3 summarizes a few of the key utilization mea-
sures for history between initial occurrence of
bleeding and entry into the trial. Because ac-
tual cost and charge data are not available from
the trial, costs from a payer reimbursement 
perspective are imputed based on average
Medicare fees. For example, for hospitaliza-
tions, the average Medicare reimbursement for
DRG 174 (GI hemorrhage with complications
or comorbid conditions) was $4,264. Commer-
cial reimbursements would be significantly
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higher. Transfusion costs are based on prior
economic analysis.33
As demonstrated in Table 3, the costs asso-
ciated with diagnosing obscure bleeding and
treating anemia and other symptoms can be
significant. Furthermore, data on other utiliza-
tion contributing to direct medical costs, such
as physician visits, emergency department vis-
its, and prescriptions, were not collected as part
of the trial. Therefore, these figures significantly
underestimate the total cost of diagnosis and ame-
liorative treatment prior to capsule endoscopy.
Two experienced gastroenterologists inde-
pendently reviewed the image stream recorded
from capsule endoscopy. Confirmation of a
bleeding site was based on agreement from
both physicians’ assessments. A bleeding site
was found through the capsule endoscopy
exam in 12 of the 20 patients participating in
the clinical trial (60% yield), and push en-
teroscopy found the cause of bleeding in seven
of 20 patients (35% yield). The fact that capsule
endoscopy provided a negative diagnosis in
eight of the 20 patients is also a meaningful di-
agnostic result. Since the Capsule was able to
view the entire small intestine in all 20 patients,
it was the only diagnostic tool able to provide
a negative diagnostic result short of intra-op-
erative exploratory surgery. The negative di-
agnostic result in these eight patients suggests
that the cause of bleeding is not within the
small intestine. The push enteroscope provided
a negative result in 13 of the 20 patients, but
the result is not as meaningful since only one-
third of the 22-foot small intestine could be
viewed.
The case for the effectiveness of capsule en-
doscopy is even further strengthened when
considering that the 20 cases in the trial were
all patients with lengthy history of bleeding
and failed efforts to determine the bleeding
source. The patients in this study averaged
more than 10 procedures without any diag-
nostic finding prior to capsule enteroscopy.
This large number of ineffective procedures is
consistent with the published literature cited
earlier in this paper. These findings do suggest
that capsule endoscopy may be an appropriate
approach to work-up prior to enteroscopy.
Perhaps most compelling in discussing the
effectiveness of capsule endoscopy as a diag-
nostic tool for obscure bleed is the data ob-
tained from the clinical trial on patient-re-
ported outcomes. Patients completed a survey
tool regarding their experience with both cap-
sule endoscopy and enteroscopy. Table 4 sum-
marizes the findings, demonstrating signifi-
cantly higher patient satisfaction with capsule
endoscopy when compared with traditional
enteroscopy.
DISCUSSION AND CONCLUSION
Review of the literature on current diagnos-
tic tools for obscure bleeding of the small in-
testine and examination of the data from the
first U.S. clinical trial of capsule endoscopy
suggest that this new technology potentially
has significant clinical, economic, and human-
istic benefits.
Clinically, capsule endoscopy appears to
have a diagnostic yield that is higher than other
endoscopic examinations of the small intestine.
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TABLE 3. PRIOR COSTS (IN DOLLARS) FOR SELECTED DIAGNOSTIC TESTS AND TREATMENTS
FOR PATIENTS SUBSEQUENTLY ENROLLED IN THE CAPSULE ENDOSCOPY CLINICAL TRIAL
Number of Estimated Cost per
Procedure events cost/event Total cost patient
Colonoscopy 73 660 48,180 2,409
Gastroscopy 83 590 48,970 2,449
Enteroscopy 22 590 12,980 649
Diagnostic radiology 38 220 8,360 418
Transfusion (red blood cell units) 588 500 294,000 14,700
Inpatient hospitalizations 61 4,264 260,104 13,005
Total 672,594 33,630
This is not surprising, since the video images
that are relayed from the capsule to the Re-
corder can be examined multiple times by one
clinician or multiple clinicians, and the Capsule
transmits images through the entire small
bowel, including areas not viewable by other
endoscopic tools. In one of the 21 cases in the
first U.S. trial of capsule endoscopy, the tech-
nology malfunctioned. As the technology is
more widely diffused into practice, the failure
rate will need to be monitored, since it may im-
pact on the estimates of cost and effectiveness.
The literature contains little information on the
failure rate of other endoscopic technologies. In
addition, the diagnostic tool is only as good as
the clinician who reviews the images, and fur-
ther research will be needed on overall diag-
nostic yield as the technology is diffused to
providers in a variety of settings. However, the
retained data in a digital format, which can be
viewed by multiple clinicians, provide exciting
opportunities for training and for quality im-
provement.
Economically, the data from the first U.S. trial
suggests a potential net cost savings associated
with capsule endoscopy, through earlier diag-
nosis, reduction in repetitive diagnostic proce-
dures, and reduction in intermediate treatment
costs pending diagnosis and resolution. The
capsule endoscopy technology on a per-unit
cost is comparable to other current endoscopic
procedures. Providers who invest in the new
technology will require training, and profes-
sional standards for use may need to be devel-
oped and monitored to ensure that inappro-
priate utilization does not result in a net
increase in payors’ reimbursements.
Finally, but most importantly from a societal
perspective, the technology has great humanis-
tic advantages. As demonstrated from clinical
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TABLE 4. PATIENT SURVEY FINDINGS
Number of subjects
responding
None or Moderate to
minimal extreme p valuea
Difficulty in swallowing capsule
Capsule endoscopy 20 1
Enteroscopy 4 17 ,0.001
Pain during the procedure
Capsule endoscopy 19 2
Enteroscopy 16 5 0.003
Discomfort during the procedure
Capsule endoscopy 20 1
Enteroscopy 8 13 ,0.001
Pain after the procedure
Capsule endoscopy 20 1
Enteroscopy 18 3 .002
Discomfort after the procedure
Capsule endoscopy 20 1
Enteroscopy 17 4 0.003
Overall discomfort with the procedure
Capsule endoscopy 19 2
Enteroscopy 4 17 ,0.001
Positive Negative
Overall impression
Capsule endoscopy 21 0
Enteroscopy 9 12 ,0.001
Preference for procedure
Capsule endoscopy 21 0
Enteroscopy 6 15 ,0.001
aAll comparisons, using two-sided paired t tests, were statistically significant.
trial data, capsule endoscopy results in less
pain, discomfort, and anxiety. The ability to es-
tablish an early diagnosis also averts needless
worry, inconvenience, and out-of-pocket costs
to the patient.
These principles are illustrated by many of
the 20 cases in the first U.S. clinical trial. For
example, the clinical summary for patient HPO
is presented:
A 45-year-old attorney who has no signif-
icant past medical history, developed ob-
scure GI bleeding 7 months prior to refer-
ral. He had 3 episodes of maroon blood
per rectum and was hospitalized three
times. His hemoglobin fell to 7 grams and
he was transfused 3 units of packed cells.
Prior evaluation included 2 colonoscopies,
2 upper endoscopies, a push enteroscopy,
and a bleeding scan. All tests were nega-
tive. Capsule endoscopy revealed a tumor
in the ileum. Subsequent push entero-
scopy to 2.5 meters failed to reach this le-
sion and the exam was therefore normal.
The patient underwent directed laparos-
copy and a 1.5 cm tumor was found in the
distal ileum. The lesion was a carcinoid.
In this case, capsule endoscopy identified
a tumor that was not diagnosable by any
other means.
In summary, capsule endoscopy is a promis-
ing new technology on many levels. Its diag-
nostic yield is high, with the potential to result
in earlier diagnosis. This in turn can result in
more timely treatment and lower overall uti-
lization and cost. While further study is
needed, it also appears that capsule endoscopy
may greatly improve patient safety and reduce
the occurrence of adverse events associated
with more invasive exploratory diagnostic pro-
cedures. Humanistic outcomes, such as patient
comfort, satisfaction, quality of life, and pro-
ductivity, all appear to be significantly im-
proved as well.
The cost per capsule endoscopy exam and
the clinical activity and intensity appear simi-
lar to those of sonde enteroscopy. However, the
potential overall cost savings may be signifi-
cant, and the cost-effectiveness of capsule en-
doscopy, when used appropriately, may prove
to be highly favorable. Clearly, broad accep-
tance, adoption, and diffusion of new tech-
nologies needs to be driven by evidence. How-
ever, the business case and outcomes data
presented above suggest that this new tech-
nology already has a place in the diagnostic
toolkit, and that the need for further economic
evaluation should not come at the expense of
making this FDA-cleared technology available
immediately, for the work-up of obscure in-
testinal bleeding.
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